-
Posted by
Two Blokes Apr 19 -
Filed in
Stock
-
8 views
Lisata Therapeutics Inc earlier this week discussed the potential of certepetide in antibody-drug conjugate (ADC) applications through a new collaboration with Catalent. The company told investors that it entered a research license agreement with Catalent to evaluate certepetide as a payload in SMARTag dual-payload ADCs.
